Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
47.48
+0.01 (0.02%)
At close: Mar 3, 2026, 4:00 PM EST
47.48
0.00 (0.00%)
After-hours: Mar 3, 2026, 5:42 PM EST
Royalty Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 47.75, with a low estimate of 42 and a high estimate of 54. The average target predicts an increase of 0.57% from the current stock price of 47.48.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 27, 2026.
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $48 → $50 | Strong Buy | Maintains | $48 → $50 | +5.31% | Jan 27, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | -5.22% | Dec 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $54 | Buy | Maintains | $55 → $54 | +13.73% | Oct 10, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | -11.54% | Sep 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | -11.54% | Jul 22, 2025 |
Financial Forecast
Revenue This Year
3.31B
from 2.38B
Increased by 39.10%
Revenue Next Year
3.47B
from 3.31B
Increased by 5.02%
EPS This Year
5.19
from 1.78
Increased by 191.17%
EPS Next Year
5.91
from 5.19
Increased by 14.02%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.6B | 3.9B | |||
| Avg | 3.3B | 3.5B | |||
| Low | 2.6B | 2.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 52.6% | 19.0% | |||
| Avg | 39.1% | 5.0% | |||
| Low | 8.4% | -21.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.72 | 6.97 | |||
| Avg | 5.19 | 5.91 | |||
| Low | 4.49 | 5.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 221.2% | 34.4% | |||
| Avg | 191.2% | 14.0% | |||
| Low | 152.0% | 3.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.